Arcoma Financial Statements From 2010 to 2024
| ARCOMA Stock | SEK 10.45 0.20 1.88% |
Check Arcoma AB financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcoma AB's main balance sheet or income statement drivers, such as , as well as many indicators such as . Arcoma financial statements analysis is a perfect complement when working with Arcoma AB Valuation or Volatility modules.
Arcoma |
Arcoma AB Company Current Valuation Analysis
Arcoma AB's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Arcoma AB Current Valuation | 112.49 M |
Most of Arcoma AB's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arcoma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Arcoma AB has a Current Valuation of 112.49 M. This is 99.22% lower than that of the Healthcare sector and 99.09% lower than that of the Medical Devices industry. The current valuation for all Sweden stocks is 99.32% higher than that of the company.
Arcoma AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Arcoma AB's current stock value. Our valuation model uses many indicators to compare Arcoma AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arcoma AB competition to find correlations between indicators driving Arcoma AB's intrinsic value. More Info.Arcoma AB is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.52 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Arcoma AB is roughly 1.94 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Arcoma AB by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Arcoma AB's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Arcoma AB Financial Statements
Arcoma AB stakeholders use historical fundamental indicators, such as Arcoma AB's revenue or net income, to determine how well the company is positioned to perform in the future. Although Arcoma AB investors may analyze each financial statement separately, they are all interrelated. For example, changes in Arcoma AB's assets and liabilities are reflected in the revenues and expenses on Arcoma AB's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Arcoma AB. Please read more on our technical analysis and fundamental analysis pages.
Arcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray and radiography systems for radiographic applications, as well as for use in general, eneral, muscleskeleton, thoratic, pediatric, and traumaresus clinics. Arcoma AB is traded on Stockholm Stock Exchange in Sweden.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Arcoma Stock
Arcoma AB financial ratios help investors to determine whether Arcoma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Arcoma with respect to the benefits of owning Arcoma AB security.